Skip to main content
. 2017 Mar 31;8(22):36319–36330. doi: 10.18632/oncotarget.16751

Figure 7. Inhibition of xenograft tumor growth by trametinib.

Figure 7

(A) Time course of NOZ cell-derived xenograft tumor growth, measured as tumor volume in mice treated with vehicle control or trametinib, 1 mg/kg orally, at the indicated time point. Data were presented as mean ± SD (n = 4/group). Arrow represents time point of tumor cell injection. (B) Shown is representative picture of tumor growth in mice treated with vehicle control (DMSO) and the indicated dose of trametinib (left and middle panels). Bar graphs represent mean of the tumor weight from control and trametinib-treated mice (right panel). Data were presented as mean ± SD (n = 4/group). (C) Tumor sections were subjected to immunohistochemistry using specific primary antibodies, including p-ERK, p-GSK-3β and β-catenin. (D) Shown is representative Ki-67 staining of xenograft tumors from control and trametinib-treated mice. Scale bars, 200 μm. Bar graphs represent mean ± SD of the numbers of Ki-67-positive cells from 5 microscopic fields in each group. Data were presented as mean ± SD. Statistically significant differences were indicated: **P < 0.01; ***P < 0.001.